Discovery and structure-activity relationship of coumarin derivatives as TNF-α inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 10, 2004, Pages 2411-2415

  Cheng, Jie Fei ^a,c   Chen, Mi ^a   Wallace, David ^a   Tith, Sovouthy ^a   Arrhenius, Thomas ^a   Kashiwagi, Hirotaka ^b   Ono, Yoshiyuki ^a,b   Ishikawa, Akira ^a,b   Sato, Haruhiko ^b   Kozono, Toshiro ^b   Sato, Hediki ^b   Nadzan, Alex M ^a  

^a LLC   (United States)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c Tanabe Research Laboratories   (United States)

Author keywords

Coumarin; TNF

Indexed keywords

BLOCKING AGENT; COUMARIN DERIVATIVE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CELLS, CULTURED; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS);

EID: 11144356362     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.022     Document Type: Article

References (23)

1. Locksley R.M., Killeen N., Lenardo M.J. Cell. 104:2001;487.
2. Hsu H., Huang J., Shu H.B., Baichwal V., Goeddel D.V. Immunity. 4:1996;387.
3. Palanki M.S.S., Erdman P.E., Gayo-Fung L.M., Shevlin G.I., Sullivan R.W., Suto M.J., Goldman M.E., Ransone L.J., Bennett B.L., Manning A.M. J. Med. Chem. 43:2000;3995.
4. Beutler B. Tumor Necrosis Factor. 1992;Raven, New York.
5. Black R.A., Bird T.A., Mohler K.M. Annu. Rep. Med. Chem. 30:1997;241.
6. Moreland L.W. Exp. Opin. Invest. Drugs. 8:1999;1443.
7. Mikuls T.R., Moreland L.W. Exp. Opin. Pharmacother. 2:2001;75.
8. Blam M.E., Stein R.B., Lichtenstein G.R. Am. J. Gastroenterol. 96:2001;1977.
9. Assche V.G., Rutgeerts P. Exp. Opin. Invest. Drugs. 9:2000;103.
10. Palladino M.A., Bahjat F.R., Emmanuel A., Theodorakis E.A., Moldawer L.L. Nature Rev.: Drug Discov. 2:2003;736.
11. Thalimide and analogs: Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G.J. Exp. Med. 173:1991;699.
12. Niwayama S., Turk B., Liu J. J. Med. Chem. 39:1996;3044.
13. Miyachi H., Azuma A., Hiioki E., Iwasaki S., Kobayashi Y., Hashimoto Y. Biochem. Biophys. Res. Commun. 226:1996;439.
14. PDE-IV inhibitors and MMP inhibitors: Nelson F.C., Zask A. Exp. Opin. Invest. Drugs. 8:1999;383.
15. Lowe C. Exp. Opin. Ther. Pat. 8:1998;1309.
16. Adenosine agonists: Sajjadi F.G., Takabayashi K., Foster A.C., Domingo R.C., Firestein G.S. J. Immunol. 156:1996;3435.
17. Parmely M.J., Zhou W.W., Edwards C.K., Borcherding D.R., Silverstein R., Morrison D.C. J. Immunol. 151:1993;389.
18. Cheng J.-F., Ishikawa A., Ono Y., Arrhenius T., Nadzan A. Bioorg. Med. Chem. Lett. 13(21):2003;3647-3650.
19. Usgaonkar R.N., Thakor V.M., Jadhav G.V., Shab R.C. J. Indian Chem. Soc. 30:1953;743.
20. The in vivo TNF-α inhibition assay was conducted with male SD rats ( n=3 ). LPS (E. coli B055/B5, 0.1 mg/kg) challenge was performed 2 h before the subcutaneous (sc) administration of test compounds, which was generally dissolved in a mixture solvent of 20% EtOH and 80% PEG400. The pyridine-containing compounds, for example, 22 and 27, were dissolved in saline as hydrochloric acid salt formed in situ. The rats were sacrificed and bled 90 min later and the serum TNF-α activity was measured using ELISA kits. Percent inhibition of TNF-α production at 100 mg/kg was determined by comparison of yield with a control to which no test compound was added. See also: Wadsworth S.A., Cavender D.E., Beers S.A., Lalan P., Schafer P.H., Malloy E.A., Wu W., Fahmy B., Olini G.C., Davis J.E., Pellegrino-Gensey J.L., Wachter M.P., Siekierka J.J. J. Pharmacol. Exp. Ther. 291:1999;680.
21. Corsini E., Lucci L., Binaglia M., Viviani B., Bevilacqua C., Monastra G., Marinovich M., Galli C.L. Eur. J. Pharmacol. 418:2001;231-237.
22. Squadrito F., Altavilla D., Zingarelli B., Ioculano M., Calapai G., Campo G.M., Miceli A., Prosdocimi M., Caputi A.P. Life Sci. 53:1993;341-355.
23. Heguy A., Cai P., Meyn P., Houck D., Russo S., Michitsch R., Pearce C., Katz B., Bringmann G., Feineis D., Taylor D.L., Tyms A.S. Antiviral Chem. Chemother. 9:1998;149-155.